Provided by Tiger Trade Technology Pte. Ltd.

MannKind

5.66
+0.03000.53%
Post-market: 5.670.0100+0.18%19:59 EST
Volume:2.07M
Turnover:11.74M
Market Cap:1.74B
PE:57.82
High:5.77
Open:5.66
Low:5.62
Close:5.63
52wk High:6.51
52wk Low:3.38
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.95
T/O Rate:0.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0979
EPS(LYR):0.1000
ROE:32.74%
ROA:9.95%
PB:-39.01
PE(LYR):56.60

Loading ...

MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential

TIPRANKS
·
Feb 10

BRIEF-Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)

Reuters
·
Feb 09

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

TIPRANKS
·
Feb 09

FDA prüft Zulassung von Afrezza Inhalationsinsulin für Kinder und Jugendliche

Reuters
·
Feb 09

MannKind Announces First Patient Enrolled in Inhale-1St Pediatric Study Evaluating Afrezza® for Youth With Newly-Diagnosed Type 1 Diabetes (T1d)

THOMSON REUTERS
·
Feb 09

Does Afrezza’s New Dosing Label Meaningfully Change The Bull Case For MannKind (MNKD)?

Simply Wall St.
·
Feb 07

The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update

Simply Wall St.
·
Jan 31

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies

Reuters
·
Jan 26

MannKind Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 26

MannKind Shares Rise 5% Premarket After US FDA Updates Label for Inhaled Insulin Afrezza

THOMSON REUTERS
·
Jan 26

BUZZ-U.S. STOCKS ON THE MOVE-Baker Hughes, Allied Gold Corp, MannKind Corp

Reuters
·
Jan 26

MannKind receives FDA approval for Afrezza dosage label

TIPRANKS
·
Jan 26

BRIEF-MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Reuters
·
Jan 26

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance When Switching From Multiple Daily Injections (Mdi) or Insulin Pump Mealtime Therapy

THOMSON REUTERS
·
Jan 26

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Dow Jones
·
Jan 18

MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch

TIPRANKS
·
Jan 17

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Dow Jones
·
Jan 13

How 2026 FDA Decisions on Afrezza and FUROSCIX At MannKind (MNKD) Have Changed Its Investment Story

Simply Wall St.
·
Jan 10

Stuart A. Tross, Chief People & Workplace Officer, Reports Disposal of MannKind Corporation Common Shares

Reuters
·
Jan 10

Assessing MannKind (MNKD) Valuation As Regulatory Catalysts And Pipeline Updates Draw Investor Attention

Simply Wall St.
·
Jan 09